Drug Search Results
More Filters [+]

Evodenoson

Alternative Names: evodenoson, de-112
Latest Update: 2012-12-17
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ADORA2 Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Ocular,Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Santen
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Evodenoson

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hypertension|Glaucoma, Open-Angle

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT01279083

P2

Completed

Hypertension|Glaucoma, Open-Angle

2011-11-01

Recent News Events

Date

Type

Title